Stomach cancer screening

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]

Stomach cancer Microchapters


Patient Information


Historical Perspective




Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic study of choice


History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Stomach cancer screening

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer screening

CDC on Stomach cancer screening

Stomach cancer screening in the news

Blogs on Stomach cancer screening

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer screening


The two main modalities for gastric cancer screening are upper endoscopy and contrast radiography. Universal screening is recommended in countries with a high incidence of gastric cancer such as East Asian countries. In areas of low gastric cancer incidence, screening for gastric cancer with upper endoscopy should be reserved specifically for high-risk subgroups. Upper endoscopy has a sensitivity of 69 % and upper GI series has a sensitivity of 37%. Both studies have a specificity of 96%.


 The two main modalities for gastric cancer screening are upper endoscopy and contrast radiography.

Upper endoscopy

Contrast radiography

Sensitivity of tests

Screening Strategies

Universal screening

  • Screening interval is recommended to be every two years but may be widened to a three-year interval without significant effect.[7]

Selective screening of high-risk subgroups


  1. Pisani P, Oliver WE, Parkin DM, Alvarez N, Vivas J (1994). "Case-control study of gastric cancer screening in Venezuela". Br J Cancer. 69 (6): 1102–5. PMC 1969457. PMID 8198977.
  2. Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE, Eliasoph J; et al. (1984). "Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study". Ann Intern Med. 101 (4): 538–45. PMID 6383166.
  3. Longo WE, Zucker KA, Zdon MJ, Modlin IM (1989). "Detection of early gastric cancer in an aggressive endoscopy unit". Am Surg. 55 (2): 100–4. PMID 2916797.
  4. Choi KS, Jun JK, Suh M, Park B, Noh DK, Song SH; et al. (2015). "Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea". Br J Cancer. 112 (3): 608–12. doi:10.1038/bjc.2014.608. PMC 4453643. PMID 25490528.
  5. Llorens P (1991). "Gastric cancer mass survey in Chile". Semin Surg Oncol. 7 (6): 339–43. PMID 1759081.
  6. Choi IJ (2014). "Endoscopic gastric cancer screening and surveillance in high-risk groups". Clin Endosc. 47 (6): 497–503. doi:10.5946/ce.2014.47.6.497. PMC 4260096. PMID 25505714.
  7. Park CH, Kim EH, Chung H, Lee H, Park JC, Shin SK; et al. (2014). "The optimal endoscopic screening interval for detecting early gastric neoplasms". Gastrointest Endosc. 80 (2): 253–9. doi:10.1016/j.gie.2014.01.030. PMID 24613579.
  8. Tersmette AC, Goodman SN, Offerhaus GJ, Tersmette KW, Giardiello FM, Vandenbroucke JP; et al. (1991). "Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients". Am J Epidemiol. 134 (1): 14–21. PMID 1853856.

Template:WH Template:WS